Extended-Release Buprenorphine: Supporting Stability in OUD Treatment

For providers treating patients with opioid use disorder (OUD), maintaining consistency in care can be a challenge – especially when daily medication routines become a barrier.

Extended-release buprenorphine offers a long-acting treatment option that supports stability and continuity of care. Administered as a weekly or monthly injection, it provides consistent medication delivery without the need for daily dosing.

At Behavioral Health Group (BHG), we incorporate this medication into comprehensive, evidence-based care plans tailored to each patient.

What Is Extended-Release Buprenorphine?

This medication is an FDA-approved injectable medication for OUD that delivers steady therapeutic levels over time.

By removing the need for daily dosing, this treatment option can help reduce variability in adherence and support more consistent engagement in care.

Why Consider This Option for Patients

For some patients, extended-release buprenorphine may offer advantages, particularly for those who benefit from structured, long-acting treatment approaches.

Potential considerations include:

• Supporting adherence through consistent medication delivery
• Reducing the risk of missed doses or diversion
• Enabling smoother transitions from acute, inpatient or correctional settings
• Allowing patients to focus on counseling, employment and recovery goals

Explore our provider resource that outlines additional clinical considerations and patient selection guidance.

Download Our Guide Today